INT289308

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.27
First Reported 2009
Last Reported 2009
Negated 1
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 1.05
Pain Relevance 0.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Serpinb1b) cytoplasm (Serpinb1b)
Serpinb1b (Mus musculus)
Pain Link Frequency Relevance Heat
antagonist 28 99.48 Very High Very High Very High
corticosteroid 34 94.48 High High
Inflammation 10 66.16 Quite High
agonist 38 5.00 Very Low Very Low Very Low
tolerance 12 5.00 Very Low Very Low Very Low
qutenza 4 5.00 Very Low Very Low Very Low
Inflammatory mediators 4 5.00 Very Low Very Low Very Low
depression 2 5.00 Very Low Very Low Very Low
headache 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Asthma 112 92.56 High High
Pulmonary Disease 6 85.40 High High
INFLAMMATION 14 66.16 Quite High
Rhinitis 4 64.16 Quite High
Airway Obstruction 28 19.80 Low Low
Dyspnea 28 5.00 Very Low Very Low Very Low
Syndrome 16 5.00 Very Low Very Low Very Low
Injury 8 5.00 Very Low Very Low Very Low
Cough 6 5.00 Very Low Very Low Very Low
Suicidal Behaviour 4 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Pranlukast showed a similar protective effect after 14 days of treatment in a Japanese study.83 Other inhibitors of the activity of leukotrienes such as ziluton, a leukotriene synthesis inhibitor, have also shown beneficial effects in patients with EIB.80 In most countries, only the LTRA montelukast has received approval by drug regulatory agencies for prevention of EIB.
Regulation (approval) of Negative_regulation (prevention) of EIB associated with antagonist
1) Confidence 0.27 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2789687 Disease Relevance 0.35 Pain Relevance 0.17
This is true in the majority of studies dating back to the 1980s in patients with EIB.50–53 Although immediately after inhalation there can be demonstrated a modest improvement in FEV1, presumably from a decrease in bronchomotor tone, there is little effect on the prevention of EIB and in the majority of patients they are not used as such.


Neg (little) Regulation (effect) of Negative_regulation (prevention) of EIB
2) Confidence 0.16 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2789687 Disease Relevance 0.69 Pain Relevance 0.22

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox